acromegaly
ACROMEGALY
Acromegaly is a chronic, slowly developing disease with progressive disfigurement and disability. An early diagnosis is difficult as most signs and symptoms are due to long-standing overproduction of growth hormone &/or insulin-like growth factor (IGF-I) causing metabolic, endocrine and morphological changes.
Surgical intervention is the first-line of treatment for almost all patients with acromegaly unless there are contraindications or the patient refuses to undergo the procedure.

Radiotherapy

  • Considered as an adjunctive treatment in patients not fully responding to surgical or pharmacological therapy
  • Should generally be reserved as third-line treatment in patients who have not achieved tumor growth control or normalization of hormone levels with surgery and/or medical therapy
  • May also be used in patients receiving growth hormone receptor antagonist (who have failed other medical therapies) and are at risk of tumor growth
  • Other endocrinologists have used radiotherapy in patients controlled on medical therapy to allow termination of such therapy (which is potentially lifelong)
  • Conventional radiotherapy can normalize insulin-like growth factor-I and lower growth hormone levels in >60% of patients
    • However, maximum response is achieved 10-15 years after administration of radiotherapy
    • Medical therapy with somatostatin analogues is usually required during this latency period
  • Choice of technique depends on tumor characteristics
    • Conventional radiotherapy is preferred for large tumor remnants or tumors that are near to optic pathways
    • Stereotactic radiotherapy is the choice for smaller tumor size or if convenience for patient is desired
  • Main limitations of radiation therapy is safety, with hypopituitarism observed in >50 % of patients
    • Advise patients that serial pituitary function follow-up is needed to evaluate for hypopituitarism
    • Follow-up includes assessment of thyroid, adrenal and gonadal functions at least annually
  • Conventional radiotherapy may carry risk of second tumors or cerebrovascular events due to radiation vasculopathy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
21 Dec 2017
Vitamin C supplementation appears to yield significant reductions in glucose concentrations in patients with diabetes, particularly older individuals and those with more prolonged supplementation, according to a study.
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
01 Dec 2014

Q: Introduction to perimenopause – when it begins, what are the signs and symptoms?
A: Many women do not realize that menopause does not happen over 24 hours. For a period of 10 to 15 years before menopause is established at the average age of 51, a woman will already be undergoing a period of change in a phase of life known as perimenopause or ‘around menopause’. Perimenopause is typically experienced by women aged between 40 and 56.

Jairia Dela Cruz, 27 Dec 2017
Individuals with obesity and high abdominal fat mass appear to have a twofold increased risk of developing psoriasis, as shown in a study. Long-term weight gain of ≥10 kg is also associated with a substantially increased risk.